Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says that as the most common infectious cause of long-term disability CMV should be the number one target of vaccine development.
First of four parts
Cytomegalovirus (CMV) is a common herpesvirus that doesn’t cause symptoms in adults and children with intact immune systems.
But there is a risk of transmission to infants when pregnant women are infected, and about 25% of infected infants experience some kind of long-term disease, including but not limited to hearing loss, developmental disorders and seizure disorders.
“It being the most common infectious cause of long-term disabilities makes it as far as I am concerned target number for the next important pathogen that we’ re combating through vaccination,” Sallie Permar, M.D., Ph.D., said in an interview with Managed Healthcare Executive.
Permar spoke about CMV vaccine development this afternoon at the IDWeek 2023 meeting in Boston. She is a leading researcher of neonatal viral infections, including HIV as wells as CMV, and vertical transmission from mothers to infants. Permar is chair of the Department of Pediatrics at Weill Cornell Medicine and pediatrician-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center and the NewYork-Presbyterian Komansky Children’s Hospital.
In her conversation with MHE, discussed CMV incidence and prevalence, the hurdles to developing a vaccine and two of the leading vaccine candidates in development.
“We all jumped to the moment when the Zika epidemic came in 2015, 2016 and was recognized to be a congenital pathogen at that time. CMV is like a Zika epidemic, times 10, every year, as long as we’ve known. So it is public health but it just hasn’t changed and not a lot of people know about it.”
With Its Future in Doubt, One of the Architects Makes a Case for PEPFAR | IDWeek 2023
October 15th 2023Mark Dybul, M.D., the keynote speaker for the closing session of the IDWeek meeting in Boston, delivered an impassioned defense of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) as its reauthorization by Congress has got ensnarled in abortion issues.
Read More
Cytomegalovirus Update: For the First Time, a Phase 3 Vaccine Trial | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center spoke about the phase 3 trial of Moderna’s mRNA vaccine against CMV and another candidate being developed by Merck that showed some promise in a phase 2B trial.
Read More
Cytomegalovirus Update: Why Isn’t There a Vaccine? | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says lack of awareness and funding as well as some characteristics of the virus itself have slowed development of vaccine against CMV.
Read More
Cytomegalovirus Update: Congenital CMV Is a ‘Disease of Disparity’ | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says the epidemiology of congenital CMV hasn’t varied much over the years and that the condition does disproportionately affect lower socioeconomic populations and communities of color in the U.S.
Read More